Exempt Drugs from Prescription Drug Affordability Board Reviews

Summary

The bill would stop the Colorado Prescription Drug Affordability Review Board from reviewing the cost or setting price caps for three groups of prescription drugs: those containing cannabis, those the FDA has designated for rare diseases, and biologics made from human whole blood or plasma. It would apply to any such drug sold in the state, removing them from the board’s affordability review process. Proponents argue it protects access to specialized medicines, while critics say it limits the board’s ability to control drug prices.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share